Results 161 to 170 of about 18,729 (264)

The efficiency of endothelin receptor antagonist bosentan for pulmonary arterial hypertension associated with congenital heart disease: A systematic review and meta-analysis. [PDF]

Medicine (Baltimore), 2018
Kuang HY, Wu YH, Yi QJ, Tian J, Wu C, Shou WN, Lu TW.   +6 more
europepmc   +1 more source

Liver toxicity: the Achilles' heel of endothelin receptor antagonist therapy?

European Respiratory Journal, 2009
M. Hoeper
semanticscholar   +1 more source

The Endothelin Receptor Antagonist Macitentan Improves Isosorbide-5-Mononitrate (ISMN) and Isosorbide Dinitrate (ISDN) Induced Endothelial Dysfunction, Oxidative Stress, and Vascular Inflammation. [PDF]

Oxid Med Cell Longev, 2018
Steven S, Oelze M, Hausding M, Roohani S, Kashani F, Kröller-Schön S, Helmstädter J, Jansen T, Baum C, Iglarz M, Schulz E, Münzel T, Daiber A.   +12 more
europepmc   +1 more source

Beyond vasodilator: anti-apoptotic effect of endothelin receptor antagonist. [PDF]

Korean Circ J, 2014
Chang SA.
europepmc   +1 more source

Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension.

Circulation, 2000
D. Williamson, Lucinda L. Wallman, Richard Jones, A. Keogh, Frances Scroope, R. Penny, C. Weber, P. Macdonald   +7 more
semanticscholar   +1 more source

Targeting Peptidergic Systems for Melanoma Treatment. [PDF]

Cancers (Basel)
Sánchez ML, Mehboob R, Coveñas R.
europepmc   +1 more source

Progress in mechanistic and clinical translational research of endothelin A receptor antagonists in the treatment of diabetic kidney disease: a narrative review. [PDF]

Front Endocrinol (Lausanne)
Li M, Xie C, Qiu Y, Li X, Han G, Ma N, Wang G.   +6 more
europepmc   +1 more source

Comparing bridging drug therapy approaches prior to balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension: a prospective analysis from the national UK CURATE registry. [PDF]

Open Heart
Li OM, Ghani H, Appenzeller P, Amaral-Almeida L, Bambrough P, Cannon JE, Taboada D, Bunclark KL, Toshner M, Sheares K, Coghlan JG, Pepke-Zaba J, Hoole SP.   +12 more
europepmc   +1 more source

Aprocitentan: An oral, once-daily antihypertensive therapy for resistant hypertension in adult patients. [PDF]

Heart Int
Valdes PO, Pickard B, Orakwue C, Ferdinand K.   +3 more
europepmc   +1 more source